Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Tuesday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of NASDAQ:ADXS opened at $0.03 on Tuesday. The stock has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.81. The company’s fifty day moving average is $0.05 and its 200 day moving average is $0.11. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.